CTOs on the Move

biOasis Technologies Inc

www.bioasis.ca

 
biOasis Technologies Inc., an early stage biopharmaceutical company, engages in the research, development, and commercialization of technologies and products for the diagnosis and treatment of central nervous system diseases and disorders. The company develops Transcend program, a protein vector, which is a proprietary carrier for the transport of therapeutic agents across the blood brain barrier for treatment of a range of neurological, oncological, and infectious disease applications; and Cognitest, a proprietary in vitro diagnostic assay for Alzheimer’s disease. It has a collaborative research agreement with the University of British Columbia to assist the company in development of an enzyme linked ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.bioasis.ca
  • 3489 Canterbury Pl
    Surrey, BC CAN V3S 0G8
  • Phone: 604.542.5059

Executives

Name Title Contact Details

Similar Companies

Interleukin Genetics

Interleukin Genetics Incorporated is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MindMaze

MindMaze is pioneering a breakthrough computing platform that captures brain activity upon intent, creating a new operating system for computers - a brain O/S - with initial applications in the healthcare and gaming industries.

Chi Scientific

Chi Scientific is a Maynard, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genmab

Genmab is a leading international biotechnology company that aims to improve the lives of patients by creating and developing innovative antibody products. The company was founded in Copenhagen, Denmark in 1999. Genmab`s ordinary shares are publicly traded on Nasdaq Copenhagen and American Depositary Shares under its ADR Program are listed in the United States on the Nasdaq Global Select Market. Genmab is developing a pipeline of antibody therapeutics with eighteen products in clinical development, including two marketed products, DARZALEX® (daratumumab) and Arzerra® (ofatumumab), and approximately 20 in-house and partnered pre-clinical programs. Our pipeline currently includes naked antibodies, Antibody Drug Conjugates (ADCs), bispecific antibodies created from our DuoBody® technology platform, and antibodies created with our HexaBody® technology.

Progenity

Progenity, Inc. is a biotechnology company innovating in the fields of women`s health, gastrointestinal health, and oral biotherapeutics. Progenity applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity`s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.